Literature DB >> 29235433

Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015.

Y J Park1, J M Kim2, B R Lee3, T H Kim4, E G Lee1.   

Abstract

This study evaluated the annual prevalence of anogenital warts (AGW) caused by human papillomavirus (HPV) and analysed the trend in annual per cent changes (APC) by using national claims data from the Health Insurance Review and Assessment of Korea, 2007-2015. We also estimated the socio-economic burden and co-morbidities of AGW. All analyses were performed based on data for primary A63.0, the specific diagnosis code for AGW. The socio-economic cost of AGW was calculated based on the direct medical cost, direct non-medical cost and indirect cost. The overall AGW prevalence and socio-economic burden has increased during the last 9 years. However, the prevalence of AGW differed significantly by sex. The female prevalence increased until 2012, and decreased thereafter (APC + 3·6%). It would fall after the introduction of routine HPV vaccination, principally for females, in Korea. The male prevalence increased continuously over time (APC + 11·6%), especially in those aged 20-49 years. Referring to the increasing AGW prevalence and its disease burden, active HPV infection control surveillance and prevention in males are worth consideration.

Entities:  

Keywords:  Big data analysis; genital warts; human papillomavirus vaccine; sexually transmitted disease; urogenital infection

Mesh:

Substances:

Year:  2017        PMID: 29235433      PMCID: PMC9134747          DOI: 10.1017/S0950268817002813

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  27 in total

1.  Human papillomavirus vaccines. WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-04-10

2.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.

Authors:  Ni Li; Silvia Franceschi; Rebecca Howell-Jones; Peter J F Snijders; Gary M Clifford
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

3.  Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations.

Authors: 
Journal:  Vaccine       Date:  2014-12-12       Impact factor: 3.641

4.  [Cost-of-illness study of asthma in Korea: estimated from the Korea National Health insurance claims database].

Authors:  Choon Seon Park; Hye-Young Kang; Il Kwon; Dae Ryong Kang; Hye Young Jung
Journal:  J Prev Med Public Health       Date:  2006-09

5.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors:  Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal:  BMJ       Date:  2010-07-20

6.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

7.  Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.

Authors:  Hammad Ali; Basil Donovan; Handan Wand; Tim R H Read; David G Regan; Andrew E Grulich; Christopher K Fairley; Rebecca J Guy
Journal:  BMJ       Date:  2013-04-18

8.  Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Harrell W Chesson; C Robinette Curtis; Julianne Gee; Joseph A Bocchini; Elizabeth R Unger
Journal:  MMWR Recomm Rep       Date:  2014-08-29

Review 9.  Systematic review of the incidence and prevalence of genital warts.

Authors:  Harshila Patel; Monika Wagner; Puneet Singhal; Smita Kothari
Journal:  BMC Infect Dis       Date:  2013-01-25       Impact factor: 3.090

10.  Prevalence and determinants of high-risk human papillomavirus infection in male genital warts.

Authors:  Sung Jin Park; Juhyung Seo; Seong-Heon Ha; Gyung-Woo Jung
Journal:  Korean J Urol       Date:  2014-03-13
View more
  3 in total

1.  Estimating the Burden of Illness Related to Genital Warts in Russia: A Cross-Sectional Study.

Authors:  Vera N Prilepskaya; Mikhail Gomberg; Smita Kothari; Karen Yee; Amit Kulkarni; Suzanne M Garland; Anna R Giuliano
Journal:  J Health Econ Outcomes Res       Date:  2020-10-07

2.  Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea.

Authors:  Young-Tak Kim; Beatriz Serrano; Jae-Kwan Lee; Hyunju Lee; Shin-Wha Lee; Crystal Freeman; Jin-Kyoung Oh; Laia Alemany; Francesc-Xavier Bosch; Laia Bruni
Journal:  Papillomavirus Res       Date:  2018-12-30

3.  North Korea Must be Global Scale Cohort, Not a Galapagos in the Medical Research Field.

Authors:  Duck Yeong Ro; Dae Hee Kim; Sae Hyun Park
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.